CORE A (Administration and Informatics) The Administrative Core is responsible for program planning and evaluation, operations management, organization of meetings, financial stewardship, and informatics services. Key Core A functions are to: ?Provide scientific and administrative oversight to all components of the Consortium. ?Coordinate communication and organize meetings between CRC investigators, staff, DSMB, external and internal advisory boards, ?Execute effective planning and evaluation systems to monitor program performance and efficiency in regards to resource management. ?Monitor for compliance with NIH, NCI, FDA, DHHS, and participating organizations, and render reports concerning such monitoring. Monitor use of human subjects, animal subjects, and tissue specimens. ?Develop and maintain specific policies and procedures to ensure the quality and confidentiality of all CRC data and associated information management systems. Maintain ongoing research into the enhancement of said policies to ensure compliance with evolving regulatory and legislative requirements. ?Manage grants/contracts, perform fiscal oversight /management, and disburse funds. ?Provide information management systems, including clinical, basic science, and administrate data collection, storage, and analysis instruments. ?Expand current information management systems to incorporate new data sets and data management requirements. ?Provide the community and CLL patients specifically, with information regarding CRC research activities and general OIL educational materials.
The primary objective of Core A is to enable the efficient and effective operation and coordination of consortium-wide projects and cores. This objective is motivated by the CRCs overall mission to help develop curative strategies for patients with Chronic Lymphocytic Leukemia.
|Hasan, M K; Yu, J; Chen, L et al. (2017) Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia 31:2615-2622|
|Patel, V M; Balakrishnan, K; Douglas, M et al. (2017) Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia 31:1872-1881|
|Patel, Viralkumar; Balakrishnan, Kumudha; Bibikova, Elena et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23:3734-3743|
|Edelmann, J; Tausch, E; Landau, D A et al. (2017) Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia 31:734-738|
|Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954|
|Vangapandu, Hima V; Jain, Nitin; Gandhi, Varsha (2017) Duvelisib: a phosphoinositide-3 kinase ?/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26:625-632|
|Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2017) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma :1-12|
|Rassenti, Laura Z; Balatti, Veronica; Ghia, Emanuela M et al. (2017) MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 114:10731-10736|
|Kipps, Thomas J; Stevenson, Freda K; Wu, Catherine J et al. (2017) Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3:16096|
|Vangapandu, Hima V; Havranek, Ondrej; Ayres, Mary L et al. (2017) B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15:1692-1703|
Showing the most recent 10 out of 552 publications